Global Event to Unveil All the Attractions of Kansai's Startup Ecosystem ”Kansai Startup Mashups in OSAKA” and public recording of TOKIO TERRACE will be held at the same time!
The OBDA, in collaboration with the Keihanshin Startup Ecosystem Consortium and JETRO Osaka, has jointly launched the brand, “Kansai Startup Mashups”. We will be holding the global event at QUINTBRIDGE in Osaka, Japan on Thursday, March 2, 2023. The open recording of TOKIO TERRACE will be held simultaneously, and the call for participants begins today.
https://www.starecokansai.com/keihanshin/kansaistartupmashups-en/
This event will feature a publicly recorded conversation between MC of the TV program TOKIO TERRACE, who illuminates the future of startup companies, and one selected startup company that is drawing attention in the Kansai region of Japan. There will be an award ceremony for companies selected this year for J-Startup KANSAI , sponsored by the Kansai Bureau of Economy, Trade and Industry, a virtual experience zone by Hiroshi Sakuma, director of Virtual Osaka for the 2025 Osaka-Kansai Expo, and sessions on the future of the Kansai region.
In the global session, there will be pitches by startups from the Kansai region that are challenging to the world and overseas startups that are trying to enter the Kansai region, as well as a session on efforts to promote open innovation between overseas startups and Japanese companies. We will create an environment in which startups and entrepreneurs who will play an active role in the world are created in the Kansai region, and entrepreneurs from Japan and abroad are attracted to Kansai, building a startup ecosystem global hub city.
This event will be held as the first step toward the creation of a system that will lead to the birth of unicorn companies from the Kansai region and the creation and support of startups that will grow to great heights in anticipation of the 2025 Osaka-Kansai Expo and the post-Expo world exposition.
Kansai Startup Mashups in Osaka
- Date/Time: March 2, 2023 at 11 a.m. - 6 p.m.(JST)
- Location: Hybrid event
-
Program
Session 1: Opening Session
Session 2: Global Session
Session 3: J-Startup KANSAI 2022 Selection Ceremony
Session 4: TOKIO TERRACE public recording
Session 5: KANSAI FUTURE Session
Session 6: Closing Session
Application URL: https://230302-mashups-osaka-en.peatix.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201006153/en/
Contact information
Innovation Promotion Department at OBDA
Person in charge: Tamashiro and Ishikawa
Tel: +81-6-6359-3004
E-mail: mashups@obda.or.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom